SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014729
Filing Date
2023-08-14
Accepted
2023-08-14 09:11:17
Documents
78
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q btai-20230630x10q.htm   iXBRL 10-Q 2117806
2 EX-31.1 btai-20230630xex31d1.htm EX-31.1 17376
3 EX-31.2 btai-20230630xex31d2.htm EX-31.2 17595
4 EX-32.1 btai-20230630xex32d1.htm EX-32.1 10356
5 EX-32.2 btai-20230630xex32d2.htm EX-32.2 8789
6 GRAPHIC btai-20230630x10q006.jpg GRAPHIC 80340
  Complete submission text file 0001558370-23-014729.txt   7927869

Data Files

Seq Description Document Type Size
7 EX-101.SCH btai-20230630.xsd EX-101.SCH 46981
8 EX-101.CAL btai-20230630_cal.xml EX-101.CAL 47224
9 EX-101.DEF btai-20230630_def.xml EX-101.DEF 194539
10 EX-101.LAB btai-20230630_lab.xml EX-101.LAB 467177
11 EX-101.PRE btai-20230630_pre.xml EX-101.PRE 357355
72 EXTRACTED XBRL INSTANCE DOCUMENT btai-20230630x10q_htm.xml XML 1191491
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38410 | Film No.: 231166696
SIC: 2834 Pharmaceutical Preparations